HUE071482T2 - (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra - Google Patents

(5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra

Info

Publication number
HUE071482T2
HUE071482T2 HUE19742480A HUE19742480A HUE071482T2 HU E071482 T2 HUE071482 T2 HU E071482T2 HU E19742480 A HUE19742480 A HU E19742480A HU E19742480 A HUE19742480 A HU E19742480A HU E071482 T2 HUE071482 T2 HU E071482T2
Authority
HU
Hungary
Prior art keywords
thiazolidine
dione
pyridin
ethoxy
hydroxyethyl
Prior art date
Application number
HUE19742480A
Other languages
English (en)
Hungarian (hu)
Inventor
Pedemonte Marc Martinell
Lalanza Maria Pilar Pizcueta
Pascau Laura Pilar Rodriguez
Original Assignee
Minoryx Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L filed Critical Minoryx Therapeutics S L
Publication of HUE071482T2 publication Critical patent/HUE071482T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE19742480A 2018-06-06 2019-06-06 (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra HUE071482T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382397 2018-06-06

Publications (1)

Publication Number Publication Date
HUE071482T2 true HUE071482T2 (hu) 2025-08-28

Family

ID=62716008

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19742480A HUE071482T2 (hu) 2018-06-06 2019-06-06 (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra

Country Status (13)

Country Link
US (2) US11957670B2 (https=)
EP (2) EP4545142A3 (https=)
JP (1) JP7376934B2 (https=)
DK (1) DK3801515T3 (https=)
ES (1) ES3028538T3 (https=)
FI (1) FI3801515T3 (https=)
HR (1) HRP20250591T1 (https=)
HU (1) HUE071482T2 (https=)
LT (1) LT3801515T (https=)
PL (1) PL3801515T3 (https=)
PT (1) PT3801515T (https=)
SI (1) SI3801515T1 (https=)
WO (1) WO2019234664A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
EP3917508A4 (en) 2019-01-28 2022-12-21 Mitochondria Emotion, Inc. EAAT2 ACTIVATORS AND METHODS OF USE THEREOF
CA3127453A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
EP3013371A4 (en) 2013-06-26 2017-04-26 Rett Syndrome Research Trust Rett syndrome and treatments therefore
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
EP3125888B1 (en) 2014-04-02 2018-05-23 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
WO2017057587A1 (ja) 2015-09-30 2017-04-06 株式会社ニコン 露光装置、フラットパネルディスプレイの製造方法、及びデバイス製造方法
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
CN106202285A (zh) 2016-06-30 2016-12-07 北京百度网讯科技有限公司 搜索结果展示方法和装置
EP3548026B1 (en) 2016-12-01 2021-01-20 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
EP3559010B1 (en) 2016-12-23 2022-06-08 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
EA202092954A1 (ru) 2018-06-06 2021-04-08 Минорикс Терапьютикс С.Л. Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей
BR112020024917A2 (pt) 2018-06-06 2021-03-09 Minoryx Therapeutics S.L. Método de administrar uma quantidade terapeuticamente eficaz de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona

Also Published As

Publication number Publication date
PT3801515T (pt) 2025-06-11
JP2021527049A (ja) 2021-10-11
EP3801515B1 (en) 2025-04-09
ES3028538T3 (en) 2025-06-19
HRP20250591T1 (hr) 2025-07-04
EP4545142A3 (en) 2025-06-11
FI3801515T3 (fi) 2025-05-27
EP4545142A2 (en) 2025-04-30
US20210228559A1 (en) 2021-07-29
SI3801515T1 (sl) 2025-07-31
JP7376934B2 (ja) 2023-11-09
US11957670B2 (en) 2024-04-16
PL3801515T3 (pl) 2025-07-14
WO2019234664A1 (en) 2019-12-12
LT3801515T (lt) 2025-06-10
DK3801515T3 (da) 2025-04-28
US20250064791A1 (en) 2025-02-27
EP3801515A1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
IL279186A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts
HUE059604T2 (hu) Eljárás 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindion és sói elõállítására
CY1124088T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
HUE071482T2 (hu) (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra
HUE054346T2 (hu) 5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-dion nem-alkoholos zsírmáj-betegség kezelésére
DK3980411T3 (da) N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2h-pyran-4-carboxamid som en human ctps1-inhibitor til behandling af proliferative sygdomme
IL279183A (en) Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione
CL2014000149A1 (es) Metodo para sintetizar n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil) fenil)]acetamida y mesilato monohidrato cristalino del mismo; composicion farmaceutica que lo contiene; combinacion farmaceutica; uso en el tratamiento y/o profilaxis de una infeccion por virus herpes simplex.
PE20190805A1 (es) Compuesto de piridina
FI3511319T3 (fi) Lysiinispesifisen demetylaasi-1:n inhibiittoreita
JP2014528450A5 (https=)
HUE051634T2 (hu) 5-[2-(Piridin-2-il-amino)-1,3-tiazol-5-il]-2,3-dihidro-1H-izoindol-1-on-származékok és alkalmazásuk delta és gamma foszfatidilinozit-3-kináz duális inhibitoraiként
HRP20260002T1 (hr) Čvrsti oblici 2-(5-(4-(2-morfolinoetoksi)fenil)piridin-2-il)-n-benzilacetamida
BR112022021951A2 (pt) Leriglitazona para o tratamento de inflamação pulmonar e doença pulmonar intersticial
HK40050840A (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
CY1120933T1 (el) Κρυσταλλος παραγωγου βενζολιου αζολης ως αναστολεας οξειδασης ξανθινης